Author

Rocío Benítez‐Fernández

Consejo Superior de Investigaciones CientíficasORCID 0000-0003-3535-4370Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Fernando de CastroiD· 2 shared Alexandre LeytensiD· 1 shared Alfonso LagaresiD· 1 shared Ana María Castaño-LeóniD· 1 shared Ana Martı́neziD· 1 shared Beatriz Fernández‐GómeziD· 1 shared Carlos Jiménez-GarcíaiD· 1 shared Carmen GiliD· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Fernando de CastroORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologyAutophagyPeer-reviewedSep 8, 2024

Targeted proteomics addresses selectivity and complexity of protein degradation by autophagy

Alexandre Leytens, Rocío Benítez‐Fernández, Carlos Jiménez-García…·Jörn Dengjel

This study uses targeted proteomics to analyze protein degradation patterns during autophagy, revealing differential responses of selective autophagy receptors to various stimuli.

19 citations

proteomicsexperimental assay

𝕏 PostBluesky

NeuroscienceBritish Journal of PharmacologyPeer-reviewedMay 14, 2024

ApTOLL, a new therapeutic aptamer for cytoprotection and (re)myelination after Multiple Sclerosis.

Beatriz Fernández‐Gómez, Miguel Marchena, David Piñeiro…·Fernando de Castro

ApTOLL, an aptamer targeting TLR4, shows immunomodulatory and remyelinating effects in MS models and cell cultures.

18 citationstop 4%

mousehuman

𝕏 PostBluesky

NeuroscienceInternational Journal of Molecular SciencesPeer-reviewedFeb 28, 2021

Dynamics of central remyelination and treatment evolution in a model of Multiple Sclerosis with Optic Coherence Tomography

Rocío Benítez‐Fernández, Carolina Melero‐Jerez, Carmen Gil…·Fernando de Castro

This study uses optical coherence tomography to monitor remyelination in MS patients and validates the therapeutic potential of VP3.15 as a remyelinating drug.

7 citations

humanimaging

𝕏 PostBluesky